Sourav Bandyopadhyay
Uses functional genomics, drug screens and proteomics to understand why breast and lung cancers become resistant to drugs, including drugs that target the mTOR pathway.
Professor, Bioengineering and Therapeutic Sciences, UCSF · PhD with Trey Ideker, UC San Diego · independent lab at UCSF since 2010
Bandyopadhyay Lab, Department of Bioengineering and Therapeutic Sciences, University of California San Francisco (San Francisco, California, USA) ↗ Lab lineagetrained under Trey Ideker →
Portrait: UCSF Profiles
Sourav Bandyopadhyay is a professor at the University of California San Francisco. He earned his PhD in bioinformatics and systems biology with Trey Ideker at UC San Diego and started his own research group at UCSF in 2010. His lab studies drug resistance and synthetic lethal interactions in breast and lung cancers.
The 2023 study in the Atlas tested RMC-6272, a bi-steric molecule: it joins a rapamycin-like part to a part that blocks the mTOR active site. It hits mTORC1 more than 25 times more strongly than mTORC2, and it blocks 4E-BP1, a target that rapamycin-type drugs miss.
In breast cancer cell lines the drug triggered cell death, worked in tumours that were resistant to hormone therapy or to CDK4/6 inhibitors, and did better than everolimus. The authors suggest selective mTORC1 inhibition could help overcome several forms of resistance.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2023 | A | A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer MEN2023 Showed that the bi-steric mTORC1-selective inhibitor RMC-6272 kills ER+ breast cancer cells and overcomes hormone and CDK4/6 inhibitor resistance; Bandyopadhyay was senior and corresponding author. |
Co-authors in the Atlas 3
People with a profile here who share at least one study with Sourav Bandyopadhyay.
ShowHide
- Delong Meng Cancer researcher at UCSF who led the preclinical test of RMC-6272, a drug that blocks mTORC1 much more strongly than mTORC2, in drug-resistant breast cancer
- Hani Goodarzi Systems biologist at UCSF and the Arc Institute who combines computation and experiments to find hidden gene-regulation programs that drive cancer, and a co-author of two Atlas studies on mTORC1 in drug-resistant cancers
- Yu Chi Yang Scientist at Revolution Medicines who worked on the company's bi-steric mTORC1-selective inhibitors, from the breast cancer lab studies of RMC-6272 to the first trial of RMC-5552 in patients
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.